spacer
home > ict > autumn 2009 > the case for digitisation
PUBLICATIONS
International Clinical Trials

The Case for Digitisation

 

Imaging core labs that use digital imaging of pathology slides are opening windows for pharmaceutical and biopharmaceutical companies to the cellular levels of illness and disease states. Digital pathology allows quick and efficient processing of subjects for inclusion and efficacy determination in clinical trials. Digital imaging uses many specimen types and stains, such as tissue biopsies and bone marrows.

For hundreds of years, skilled pathologists, physicians and surgeons have peered into the cells of patient tissues to discover disease causes or diagnose illnesses. The tools for this work included the microscope and glass slides containing specimens. Over time, slide scanners and software tools were developed, but produced very large digital images. The process was slow and storage sizes for these images meant that they were not feasible to use in large-scale clinical trial work.

DIGITAL ADVANTAGES

Today’s scanners and software use digital compression that allows for better management of slide image size. Slide scanners quickly digitise pathology specimens that enable imaging core labs to use more efficient procedures and meet tighter timelines. These scanners produce imagery in file formats and sizes that are accessible over a computer network or the internet. Imaging core labs have taken digital slide scanning one step further by using digital pathology on a worldwide scale in clinical drug trials.

Prior to the use of slide digitisation, labs prepared several sets of glass slides from each subject’s tissue block and sent them to reviewers. These glass slides would contain a different layer of tissue from the block. The chance of reviewers interpreting their specimen differently increased due to the fact that each reviewed a different layer.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Frank Dunn joined Biomedical Systems as a Medical Writer in 2006. Prior to joining the company, Frank served as a Public Affairs Specialist with the US Coast Guard and the Department of Homeland Security for 22 years. He has extensive experience in clinical trial document development and has developed tracking methods to manage multiple study processes. Frank currently oversees the document process for all imaging clinical trials at Biomedical Systems.
spacer
Frank Dunn
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement